vs
CytomX Therapeutics, Inc.（CTMX）与GREENE COUNTY BANCORP INC（GCBC）财务数据对比。点击上方公司名可切换其他公司
GREENE COUNTY BANCORP INC的季度营收约是CytomX Therapeutics, Inc.的1.2倍（$22.2M vs $18.7M），GREENE COUNTY BANCORP INC净利率更高（46.3% vs -0.8%，领先47.2%），GREENE COUNTY BANCORP INC同比增速更快（23.8% vs -25.7%），GREENE COUNTY BANCORP INC自由现金流更多（$6.2M vs $-15.8M），过去两年GREENE COUNTY BANCORP INC的营收复合增速更高（18.9% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
格林县银行股份公司是一家总部位于纽约州卡茨基尔的美国联邦注册储蓄银行，营业网点分布于纽约上州的格林县、哥伦比亚县、奥尔巴尼县、阿尔斯特县和伦斯勒县，主要服务纽约上州对应区域的客户与当地社区。
CTMX vs GCBC — 直观对比
营收规模更大
GCBC
是对方的1.2倍
$18.7M
营收增速更快
GCBC
高出49.5%
-25.7%
净利率更高
GCBC
高出47.2%
-0.8%
自由现金流更多
GCBC
多$22.0M
$-15.8M
两年增速更快
GCBC
近两年复合增速
-15.9%
损益表 — Q2 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $22.2M |
| 净利润 | $-154.0K | $10.3M |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | 52.0% |
| 净利率 | -0.8% | 46.3% |
| 营收同比 | -25.7% | 23.8% |
| 净利润同比 | 97.6% | 37.4% |
| 每股收益（稀释后） | — | $0.60 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXGCBC
| Q4 25 | — | $22.2M | ||
| Q3 25 | — | $21.5M | ||
| Q2 25 | $18.7M | $20.5M | ||
| Q1 25 | $50.9M | $20.1M | ||
| Q4 24 | $38.1M | $17.9M | ||
| Q3 24 | $33.4M | $16.9M | ||
| Q2 24 | $25.1M | $16.6M | ||
| Q1 24 | $41.5M | $15.7M |
净利润CTMXGCBC
| Q4 25 | — | $10.3M | ||
| Q3 25 | — | $8.9M | ||
| Q2 25 | $-154.0K | $9.3M | ||
| Q1 25 | $23.5M | $8.1M | ||
| Q4 24 | $18.9M | $7.5M | ||
| Q3 24 | $5.7M | $6.3M | ||
| Q2 24 | $-6.5M | $6.7M | ||
| Q1 24 | $13.8M | $5.9M |
营业利润率CTMXGCBC
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | 47.4% | ||
| Q2 25 | -6.9% | 53.5% | ||
| Q1 25 | 44.4% | 44.6% | ||
| Q4 24 | 46.4% | 45.0% | ||
| Q3 24 | 12.3% | 39.6% | ||
| Q2 24 | -33.7% | 41.2% | ||
| Q1 24 | 28.1% | 39.4% |
净利率CTMXGCBC
| Q4 25 | — | 46.3% | ||
| Q3 25 | — | 41.2% | ||
| Q2 25 | -0.8% | 45.6% | ||
| Q1 25 | 46.2% | 40.1% | ||
| Q4 24 | 49.6% | 41.7% | ||
| Q3 24 | 17.2% | 37.1% | ||
| Q2 24 | -26.0% | 40.6% | ||
| Q1 24 | 33.3% | 37.3% |
每股收益（稀释后）CTMXGCBC
| Q4 25 | — | $0.60 | ||
| Q3 25 | — | $0.52 | ||
| Q2 25 | — | $0.55 | ||
| Q1 25 | — | $0.47 | ||
| Q4 24 | — | $0.44 | ||
| Q3 24 | — | $0.37 | ||
| Q2 24 | — | $0.39 | ||
| Q1 24 | — | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $258.3M |
| 总资产 | $175.1M | $3.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTMXGCBC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | $155.5M | ||
| Q4 24 | $38.1M | $166.4M | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | $190.4M | ||
| Q1 24 | $36.2M | — |
股东权益CTMXGCBC
| Q4 25 | — | $258.3M | ||
| Q3 25 | — | $248.2M | ||
| Q2 25 | $119.9M | $238.8M | ||
| Q1 25 | $25.0M | $229.0M | ||
| Q4 24 | $-456.0K | $218.4M | ||
| Q3 24 | $-23.5M | $216.3M | ||
| Q2 24 | $-31.2M | $206.0M | ||
| Q1 24 | $-31.7M | $199.2M |
总资产CTMXGCBC
| Q4 25 | — | $3.1B | ||
| Q3 25 | — | $3.1B | ||
| Q2 25 | $175.1M | $3.0B | ||
| Q1 25 | $98.5M | $3.0B | ||
| Q4 24 | $120.5M | $3.0B | ||
| Q3 24 | $139.0M | $2.9B | ||
| Q2 24 | $159.2M | $2.8B | ||
| Q1 24 | $184.7M | $2.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $6.4M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | $6.2M |
| 自由现金流率自由现金流/营收 | -84.6% | 28.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.9% |
| 现金转化率经营现金流/净利润 | — | 0.62× |
| 过去12个月自由现金流最近4个季度 | $-77.7M | $47.3M |
8季度趋势，按日历期对齐
经营现金流CTMXGCBC
| Q4 25 | — | $6.4M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | $-15.8M | $28.0M | ||
| Q1 25 | $-21.0M | $7.3M | ||
| Q4 24 | $-19.9M | $5.3M | ||
| Q3 24 | $-20.7M | $2.1M | ||
| Q2 24 | $-19.5M | $24.9M | ||
| Q1 24 | $-26.0M | $5.6M |
自由现金流CTMXGCBC
| Q4 25 | — | $6.2M | ||
| Q3 25 | — | $6.5M | ||
| Q2 25 | $-15.8M | $27.3M | ||
| Q1 25 | $-21.2M | $7.3M | ||
| Q4 24 | $-20.0M | $5.1M | ||
| Q3 24 | $-20.7M | $2.0M | ||
| Q2 24 | $-19.6M | $23.4M | ||
| Q1 24 | $-26.2M | $4.9M |
自由现金流率CTMXGCBC
| Q4 25 | — | 28.0% | ||
| Q3 25 | — | 30.4% | ||
| Q2 25 | -84.6% | 133.3% | ||
| Q1 25 | -41.6% | 36.1% | ||
| Q4 24 | -52.5% | 28.6% | ||
| Q3 24 | -62.1% | 11.8% | ||
| Q2 24 | -78.2% | 141.2% | ||
| Q1 24 | -63.1% | 31.3% |
资本支出强度CTMXGCBC
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | 0.1% | 3.4% | ||
| Q1 25 | 0.2% | 0.3% | ||
| Q4 24 | 0.2% | 1.0% | ||
| Q3 24 | 0.1% | 0.9% | ||
| Q2 24 | 0.4% | 9.1% | ||
| Q1 24 | 0.3% | 4.2% |
现金转化率CTMXGCBC
| Q4 25 | — | 0.62× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 3.00× | ||
| Q1 25 | -0.89× | 0.91× | ||
| Q4 24 | -1.05× | 0.71× | ||
| Q3 24 | -3.61× | 0.34× | ||
| Q2 24 | — | 3.70× | ||
| Q1 24 | -1.89× | 0.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
GCBC
暂无分部数据
